Entrada Therapeutics Inc
TRDA6.020USD
+0.220+3.79%
交易中 （美東）報價延遲15分鐘
228.41M總市值
9.22本益比TTM
關於 Entrada Therapeutics Inc 公司
Entrada Therapeutics, Inc. 是一家臨牀階段的生物製藥公司，旨在通過開發一類藥物來改變患者的生活，這些藥物可以作用於長期以來被認爲無法接近的細胞內靶點。該公司的內體逃逸載體 (EEV) 療法旨在將一系列治療藥物高效地輸送到各種器官和組織中，從而提高治療指數。通過其專有的、高度通用和模塊化的 EEV 平臺 (EEV 平臺)，該公司正在構建一個強大的治療候選藥物開發組合。其首批兩種候選藥物 ENTR-601-44 和 VX-670 正在臨牀試驗中。用於治療 1 型營養不良症 (DM1) 的 VX-670 旨在阻斷信使 RNA (mRNA) 中的三聯體重複序列。ENTR-601-44 正處於 I 期臨牀試驗中。該公司還宣佈在其杜氏肌營養不良症特許經營權範圍內選定其他臨牀候選藥物 ENTR-601-45 和 ENTR-601-50。
公司簡介
公司代碼TRDA
公司名稱Entrada Therapeutics Inc
上市日期Oct 29, 2021
CEOMr. Dipal Doshi
員工數量183
證券類型Ordinary Share
年結日Oct 29
公司地址One Design Center Place
城市BOSTON
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02210
電話18573051825
網址https://www.entradatx.com/
公司代碼TRDA
上市日期Oct 29, 2021
CEOMr. Dipal Doshi
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Peter S. Kim, Ph.D.
Dr. Peter S. Kim, Ph.D.
Director
Director
104.33K
-10.60%
Dr. Natarajan Sethuraman, Ph.D.
Dr. Natarajan Sethuraman, Ph.D.
President of Research and Development
President of Research and Development
82.24K
-31.79%
Mr. Kory James Wentworth, CPA
Mr. Kory James Wentworth, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
31.84K
-27.89%
Mr. Nathan J. Dowden
Mr. Nathan J. Dowden
President, Chief Operating Officer
President, Chief Operating Officer
11.80K
-77.74%
Ms. Gina Chapman
Ms. Gina Chapman
Independent Director
Independent Director
--
--
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Dr. Kush M. Parmar, M.D., Ph.D.
Dr. Kush M. Parmar, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Dipal Doshi
Mr. Dipal Doshi
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Mary T. Thistle, CPA
Ms. Mary T. Thistle, CPA
Independent Director
Independent Director
--
--
Dr. Mahalakshmi (Maha) Radhakrishnan, M.D.
Dr. Mahalakshmi (Maha) Radhakrishnan, M.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Peter S. Kim, Ph.D.
Dr. Peter S. Kim, Ph.D.
Director
Director
104.33K
-10.60%
Dr. Natarajan Sethuraman, Ph.D.
Dr. Natarajan Sethuraman, Ph.D.
President of Research and Development
President of Research and Development
82.24K
-31.79%
Mr. Kory James Wentworth, CPA
Mr. Kory James Wentworth, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
31.84K
-27.89%
Mr. Nathan J. Dowden
Mr. Nathan J. Dowden
President, Chief Operating Officer
President, Chief Operating Officer
11.80K
-77.74%
Ms. Gina Chapman
Ms. Gina Chapman
Independent Director
Independent Director
--
--
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
收入明細
FY2025Q1
FY2024
FY2023
FY2023Q2
暫無數據
地區USD
名稱
營收
佔比
United States
20.56M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 7月18日 週五
更新時間: 7月18日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Baker Bros. Advisors LP
12.82%
MPM Capital Inc.
11.54%
5AM Ventures
11.21%
T. Rowe Price Associates, Inc.
7.11%
F. Hoffman La Roche, Ltd.
6.77%
Other
50.54%
持股股東
持股股東
佔比
Baker Bros. Advisors LP
12.82%
MPM Capital Inc.
11.54%
5AM Ventures
11.21%
T. Rowe Price Associates, Inc.
7.11%
F. Hoffman La Roche, Ltd.
6.77%
Other
50.54%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
28.19%
Investment Advisor
23.69%
Hedge Fund
14.14%
Corporation
11.35%
Venture Capital
11.34%
Private Equity
2.01%
Individual Investor
1.01%
Research Firm
0.54%
Pension Fund
0.22%
Other
7.51%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
226
35.27M
92.92%
-1.95M
2025Q1
237
37.05M
97.63%
-2.01M
2024Q4
222
37.20M
98.96%
+761.72K
2024Q3
209
35.09M
95.11%
-779.91K
2024Q2
193
34.68M
94.55%
+2.42M
2024Q1
185
31.33M
93.34%
-1.07M
2023Q4
174
31.30M
93.83%
-1.07M
2023Q3
167
31.14M
93.63%
-973.86K
2023Q2
154
30.75M
92.59%
+53.89K
2023Q1
141
30.00M
92.19%
-903.00K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Baker Bros. Advisors LP
4.87M
12.82%
--
--
Mar 31, 2025
MPM Capital Inc.
4.38M
11.54%
--
--
Mar 31, 2025
5AM Ventures
4.31M
11.35%
-100.00K
-2.27%
Jun 30, 2025
T. Rowe Price Associates, Inc.
2.70M
7.11%
-167.02K
-5.83%
Mar 31, 2025
F. Hoffman La Roche, Ltd.
2.57M
6.77%
-175.00K
-6.38%
Dec 31, 2024
Janus Henderson Investors
2.12M
5.59%
+41.29K
+1.98%
Mar 31, 2025
Merck & Co Inc
1.74M
4.58%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.73M
4.56%
+55.00
+0.00%
Mar 31, 2025
The Vanguard Group, Inc.
1.57M
4.14%
+111.36K
+7.62%
Mar 31, 2025
Fidelity Management & Research Company LLC
1.24M
3.27%
-160.10K
-11.44%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.77%
iShares Neuroscience and Healthcare ETF
0.36%
First Trust Dow Jones Select MicroCap Index Fund
0.27%
Harbor Human Capital Factor US Small Cap ETF
0.1%
Federated Hermes MDT Small Cap Core ETF
0.05%
iShares Micro-Cap ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.03%
WisdomTree US SmallCap Fund
0.03%
Avantis US Small Cap Equity ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.77%
iShares Neuroscience and Healthcare ETF
佔比0.36%
First Trust Dow Jones Select MicroCap Index Fund
佔比0.27%
Harbor Human Capital Factor US Small Cap ETF
佔比0.1%
Federated Hermes MDT Small Cap Core ETF
佔比0.05%
iShares Micro-Cap ETF
佔比0.04%
ProShares Ultra Nasdaq Biotechnology
佔比0.03%
WisdomTree US SmallCap Fund
佔比0.03%
Avantis US Small Cap Equity ETF
佔比0.03%
Invesco Nasdaq Biotechnology ETF
佔比0.03%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
